Skip to main content
Premium Trial:

Request an Annual Quote

Entelos Raises $25M in Private Financing Round

NEW YORK, Sept. 6 – In silico drug discovery company Entelos of Menlo Park, Calif., said Thursday it had raised $25 million in a private placement.

Bear Stearns Health Innoventures led the series C round of financing, while Earlybird, Equity4life, and Compaq Computer also invested in the round. Previous investors, including Abingworth Ventures, Boulder Ventures, Brentwood Ventures, Charles River Ventures, and St. Paul Ventures, also reinvested in the company.

Entelos said it would use the proceeds from the financing to expand its business development efforts and to fund internal research and development programs.

Currently, Entelos has several partnerships with pharmaceutical companies to identify pathways, prioritize drug targets, and improve the drug development process.

The company has developed PhysioLab, a system designed to allow researchers to test experiments and hypotheses in silico, predicting the results through simulation. The system is available for asthma, obesity, diabetes, and adipocytes. 

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.